JOHNSON & JOHNSON |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 145.3 USD | +0.58% |
|
-2.95% | -7.31% |
| Sales 2024 * | 88.35B 6,945B | Sales 2025 * | 90.82B 7,139B | Capitalization | 350B 27,483B |
|---|---|---|---|---|---|
| Net income 2024 * | 22.04B 1,732B | Net income 2025 * | 23.09B 1,815B | EV / Sales 2024 * | 3.89 x |
| Net cash position 2024 * | 6.18B 486B | Net cash position 2025 * | 19.02B 1,495B | EV / Sales 2025 * | 3.64 x |
| P/E ratio 2024 * |
16.1
x | P/E ratio 2025 * |
15.3
x | Employees | 131,900 |
| Yield 2024 * |
3.32% | Yield 2025 * |
3.47% | Free-Float | 77.08% |
More Fundamentals
* Assessed data
More news
Latest transcript on Johnson & Johnson
More recommendations
More press releases
More news
| 1 day | -0.46% | ||
| 1 week | -2.95% | ||
| Current month | +0.48% | ||
| 1 month | +0.48% | ||
| 3 months | -10.39% | ||
| 6 months | -6.06% | ||
| Current year | -7.31% |
1 week
143.71
146.79
1 month
143.71154.86
Current year
143.13163.58
1 year
143.13175.97
3 years
143.13186.69
5 years
109.16186.69
10 years
81.79186.69
| Managers | Title | Age | Since |
|---|---|---|---|
Joaquin Duato
CEO | Chief Executive Officer | 61 | 31/12/88 |
Joseph Wolk
DFI | Director of Finance/CFO | 57 | 31/12/97 |
James Swanson
CTO | Chief Tech/Sci/R&D Officer | 58 | 04/11/19 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Marillyn Hewson
BRD | Director/Board Member | 70 | 24/04/19 |
D. Davis
BRD | Director/Board Member | 72 | 18/06/14 |
Anne Mulcahy
BRD | Director/Board Member | 70 | 21/10/09 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 14.01% | 254 M€ | +13.27% | - | |
| 12.91% | 17 M€ | +6.09% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 30/05/24 | 145.3 | +0.58% | 8,491,111 |
| 29/05/24 | 144.4 | +0.04% | 8,263,810 |
| 28/05/24 | 144.4 | -1.76% | 10,499,829 |
| 24/05/24 | 147 | -1.82% | 9,520,576 |
| 23/05/24 | 149.7 | -2.48% | 8,000,422 |
Delayed Quote Nyse, May 30, 2024 at 09:00 pm
More quotes
Johnson & Johnson is one of the world's leading producers of healthcare products. Net sales break down by family of products as follows:
- pharmaceutical products (55.4%): drugs intended for the treatment of cardiovascular diseases, oncological diseases, gastro-intestinal illnesses, infectious, immunological, neurological, dermatological diseases, etc.;
- medical products and equipment (28.9%): diagnostic systems, orthopedic and gynecological equipment, surgical materials, etc. for use by healthcare professionals;
- consumer health products (15.7%): OTC drugs (Tylenol, Sudafed, Benadryl, Zyrtec, Motrin, Nicorette and other brands), health and beauty products (Aveeno, Clean & Clear, Dr. CI:Labo, Neutrogena and OGX), baby care products (Johnson's and Aveeno Baby), oral care products (Listerine), feminine hygiene products (Stayfree and Carefree and o.b.), wound care products (Band-Aid and Neosporin) etc.
At the end of 2022, Johnson & Johnson has 89 manufacturing facilities located in the United States (28), North America (9), Europe (27), Africa and Asia/Pacific (25).
Net sales are distributed geographically as follows: the United States (51.2%), Europe (24.7%), Asia/Pacific and Africa (17.7%) and other (6.4%).
Sector
Pharmaceuticals
Calendar
12/06/2024
- Goldman Sachs Global Healthcare Conference
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
23
Last Close Price
145.3
USD
Average target price
171.9
USD
Spread / Average Target
+18.35%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -7.31% | 350B | |
| +39.82% | 734B | |
| +32.83% | 591B | |
| +14.23% | 315B | |
| +0.86% | 276B | |
| +14.19% | 238B | |
| -6.26% | 204B | |
| +8.70% | 206B | |
| +4.51% | 161B | |
| -2.05% | 160B |
- Stock Market
- Equities
- JNJ Stock
